ID: ALA47278

Max Phase: Preclinical

Molecular Formula: C22H26N8O5

Molecular Weight: 482.50

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCCCC(=O)O)C(=O)O)cc1

Standard InChI:  InChI=1S/C22H26N8O5/c1-30(11-13-10-25-19-17(26-13)18(23)28-22(24)29-19)14-8-6-12(7-9-14)20(33)27-15(21(34)35)4-2-3-5-16(31)32/h6-10,15H,2-5,11H2,1H3,(H,27,33)(H,31,32)(H,34,35)(H4,23,24,25,28,29)

Standard InChI Key:  OOTDXCUPXQETAY-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 482.50

Molecular Weight (Monoisotopic): 482.2026

AlogP: 1.05

#Rotatable Bonds: 11

Polar Surface Area: 210.54

Molecular Species: ACID

HBA: 10

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 13

HBD (Lipinski): 7

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.36

CX Basic pKa: 2.84

CX LogP: 0.69

CX LogD: -5.63

Aromatic Rings: 3

Heavy Atoms: 35

QED Weighted: 0.24

Np Likeness Score: -0.46

References

1. Rosowsky A, Forsch R, Uren J, Wick M, Kumar AA, Freisheim JH..  (1983)  Methotrexate analogues. 20. Replacement of glutamate by longer-chain amino diacids: effects on dihydrofolate reductase inhibition, cytotoxicity, and in vivo antitumor activity.,  26  (12): [PMID:6139480] [10.1021/jm00366a012]

Source

Source(1):

• Scientific Literature